Car Charging Group (OTCBB: CCGI) $0.95. Announced Wednesday after market close a strategic partnership to incorporate electric vehicle (EV) charging stations into both existing projects as well as future design offerings of Kobi Karp Architecture & Interior Design (KKAID), located at 2915 Biscayne Boulevard, Miami, FL 33137-4197, a vertically-integrated and award winning firm specializing in international architecture, planning and interior design.
"Our portfolio includes luxury high-rise mixed-use developments, world-class hospitality and entertainment centers, high-end commercial and retail spaces. We have a long history in sustainable development. In April 2007, the United States Green Building Council (USGBC) recognized Baylights Condominium, a design project we spearhead, as the first green residential building in South Florida," said Kobi Karp, principal and founder of KKAID. "Access to charging stations for electric cars is the next must-have accessory in upscale housing and forward-thinking developers are demanding this feature be incorporated into design plans as a perk to distinguish their offerings from competitors."
What They Do: Car Charging Group, Inc. is an owner and provider of electric vehicle (EV) charging stations with the mission to build-out a nationwide infrastructure, enabling EV and PHEV owners to charge their EVs anytime, anywhere. As part of its strategy, the Company owns, provides, installs and maintains electric vehicle charging units and works with its landowner partners to identify appropriate locations for its charging stations. The Company provides convenient, safe and affordable charging stations away from home in customer-friendly public locations, including municipalities, shopping malls and parking garages.
Cardiome Pharma (Nasdaq: CRME) $6.53. and Merck (NYSE: MRK). Announced Wednesday that the intravenous (IV) formulation of BRINAVESS (vernakalant) has been granted marketing approval in the European Union, Iceland and Norway for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults: for non-surgery patients with AF of seven days or less and for post-cardiac surgery patients with AF of three days or less.
BRINAVESS acts preferentially in the atria and is the first product in a new class of pharmacologic agents for cardioversion of AF to launch in the EU.
"This medicine offers physicians, patients and hospitals an important new therapy option to use for the rapid treatment of recent-onset AF, and we are pleased to add this to our strong portfolio of medicines for cardiovascular disease," said Patrick Magri, senior vice president, general manager, Cardiovascular Franchise, Merck. "We welcome this important milestone in our collaboration with Cardiome and we look forward to launching BRINAVESS in the EU beginning in the fourth quarter of 2010."
"European approval of BRINAVESS and Merck’s subsequent launch represent an exciting juncture in Cardiome’s evolution which will provide us with our first commercial product revenues,” said Doug Janzen, president and chief executive officer of Cardiome. “This success was made possible through the commitment and hard work of our employees and our partner Merck, the support of our shareholders, and the efforts of many dedicated medical professionals and patients who have taken part in the clinical program.”
What They Do: Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system.
Orexigen Therapeutics (Nasdaq: OREX) and Takeda Pharmaceutical Company Limited, Today announced that they have entered into an exclusive partnership to develop and commercialize Contrave (naltrexone SR/bupropion SR), Orexigen's investigational drug for the treatment of obesity, in the United States, Canada and Mexico.
Contrave is a combination therapy believed to address both biological and behavioral drivers of obesity. The central pathways targeted by this treatment are involved in controlling the balance of food intake and metabolism, and regulating reward-based eating behavior. Orexigen submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Contrave on March 31, 2010 and the Prescription Drug User Fee Act (PDUFA) action date has been set for January 31, 2011.
What They Do: Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. SmallCapReview has been compensated three thousand five hundred dollars for its efforts with regards to Car Charging Group by a third party APS.
